PMID: 9420060Jan 7, 1998Paper

A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors

Antimicrobial Agents and Chemotherapy
C Shi, J W Mellors

Abstract

We have developed a new recombinant retroviral system in which a library of infectious molecular clones of human immunodeficiency virus type 1 (HIV-1) is constructed with reverse transcriptase (RT) genes derived from viral RNA sequences in plasma. HIV-1 RT is amplified from plasma HIV-1 RNA by nested RT-PCR and cloned into a RT-defective HIV-1 proviral vector (xxLAI-np), generating 10(3) to 10(4) recombinant proviral clones from each reaction. The bulk cloning products or individual molecular clones are transfected into MT-2 cells to generate infectious virus. The resultant viruses are assayed for drug susceptibility in CD4+ cell lines to determine either the dominant phenotype of the recombinant virus mixture or the phenotypes of the individual viral clones. DNA sequencing of the cloned RT genes can identify mutations associated with phenotypic resistance of clonal mixtures or individual clones. This method can be used to rapidly detect the in vivo emergence of HIV-1 quasispecies resistant to RT inhibitors.

References

Apr 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·A J JapourC S Crumpacker
May 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·C López-GalíndezM Perucho
Apr 11, 1990·Nucleic Acids Research·A MeyerhansS Wain-Hobson
Jan 20, 1994·Biochemical Pharmacology·E De Clercq
Oct 1, 1994·Antimicrobial Agents and Chemotherapy·M H NguyenJ W Mellors

❮ Previous
Next ❯

Citations

Jul 1, 2016·Journal of Virology·Jennifer M ZerbatoNicolas Sluis-Cremer
Mar 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G J Hanna, R T D'Aquila
Mar 24, 2010·Antimicrobial Agents and Chemotherapy·Nicolas A MargotMichael D Miller
Jul 11, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Evguenia S SvarovskaiaMichael D Miller
Mar 1, 2012·PloS One·Jessica H BrehmUNKNOWN AIDS Clinical Trials Group Study 175 Protocol Team
Jan 29, 2020·Antimicrobial Agents and Chemotherapy·Nicolas MargotChristian Callebaut
Oct 15, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rima KulkarniKirsten L White
Nov 17, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Andrew MulatoKirsten White
Nov 8, 2005·Journal of Clinical Microbiology·Dwight V NissleyJeffrey N Strathern
Jan 18, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Miguel E Quiñones-Mateu, Eric J Arts
Dec 21, 2007·Journal of Clinical Microbiology·Keiko KajiwaraMasao Matsuoka
Aug 17, 1999·Journal of Clinical Microbiology·J Martinez-PicadoR T D'Aquila

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.